We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Multi-Cancer Early Detection Solution to Address Unmet Medical Needs in Clinical Diagnosis

By LabMedica International staff writers
Posted on 09 Jan 2024
Print article
Image: CanScan multi-cancer early detection solution is built on highly sensitive MERCURY multi-omics technology (Photo courtesy of Geneseeq)
Image: CanScan multi-cancer early detection solution is built on highly sensitive MERCURY multi-omics technology (Photo courtesy of Geneseeq)

Early detection, diagnosis, and treatment can significantly improve the survival and quality of life of cancer patients. Tumors continuously release fragmented genomic DNA into the bloodstream, although existing testing methods may find the signal too weak to be picked up in the early stages. Now, a revolutionary multi-cancer early detection solution leverages highly sensitive multi-omics technology to detect early cancer signals as well as predict the tissue of origin (TOO).

Geneseeq Technology Inc.’s (Toronto, Canada) CanScan multi-cancer early detection solution is designed to enhance the early detection, diagnosis, and treatment of various cancers. This innovative solution harnesses the power of low-depth whole-genome sequencing (WGS) applied to circulating cell-free DNA (cfDNA) from a single tube of peripheral blood. It efficiently extracts genetic and fragmentomic features to identify early cancer signals with a high specificity of 99% and accurately predicts the TOO of cancers, thereby informing subsequent diagnostic and treatment strategies. Particularly beneficial for individuals aged 50 and older who are at an average risk of cancer, CanScan represents a significant advancement in addressing the clinical needs for early cancer detection and diagnosis. It has demonstrated superior performance compared to existing standard-of-care (SOC) screening methods, especially in detecting prevalent cancers such as prostate, lung, and liver, as well as types like esophageal, endometrial, gastric, pancreatic cancers, and lymphoma, which currently lack effective SOC screening techniques.

CanScan is built upon Geneseeq's sophisticated MERCURY multi-omics technology and its efficacy has been substantiated through the extensive DECIPHER (Detecting Early Cancer by Inspecting ctDNA Features) clinical study series, which included more than 13 types of cancer. The CanScan multi-cancer early detection solution has achieved the Breakthrough Device Designation from the US Food and Drug Administration (FDA) and is presently undergoing a comprehensive real-world assessment in a large-scale prospective multi-center trial. Additionally, as of January 2023, the CanScan assay kit has received CE approval, marking a significant milestone in its journey towards transforming cancer detection and care.

Related Links:
Geneseeq Technology Inc

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more